Ventyx Biosciences
company
About
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $176.60M
- Industries
- Biopharma,Biotechnology
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$176.60M
Ventyx Biosciences has raised a total of
$176.60M
in funding over 2 rounds. Their latest funding was raised on
Sep 19, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 19, 2022 | Post-IPO Equity | $176.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Ventyx Biosciences is funded by 1 investors.
Maven Investment Partners US
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
